FIFARMA at ISPOR: Highlights on access to innovative medicines in Chile

ISPOR Chile organized an international seminar focusing on “Health Reform, Access and Financing of Medicines” at the University of San Sebastian, on November 28th, 2018.

During this event, results from the study “Analysis of Access to Innovative Medicines in Chile compared to other OECD countries“, were presented by IQVIA at the request of FIFARMA and CIF. The study compared registration and timing of reimbursement for 247 innovative molecules in Chile vs. the same parameters for twenty-two (22) OECD member countries.

According to the results, only 5 out of the 117 molecules registered in Chile have been included under the Ricarte Soto Law or are part of the GES pathologies, which means that less than 6% of the molecules registered in Chile are included in any of the broad reimbursement mechanisms available in the country. This percentage is far from the 70% average rate shown for the other OECD member countries.

In order to highlight relevant information from the study, Daniella Rodríguez, Engagement Manager of IQVIA Colombia said: “If we look at the data analyzed, we notice that Chile has a very good average time of registration of innovative medicines, with an average of only 7 months, the fastest of the countries studied, but on the other hand, Chile shows the longest delays in including these medicines into the coverage and public financing systems”.

Chile ranks 18th, among countries included in the study, with over 18 months of delay between registration and reimbursement, which is very distant from the 13-month averaged by other members.

In addition, Jean-Jacques Duhart, Executive Vice President of CIF, added: “The results of the study show that Chilean patients have much lower financial coverage from public health insurance, and therefore less access to innovative medicines and treatments than patients from the other OECD countries. Even Mexico, which has a lower GDP per capita, offers patients health coverage 7 times higher than Chile”.

Sharing the innovative pharmaceutical industry’s perspective, Luis Villalba, Executive Director of FIFARMA, indicated that: “Being able to develop and understand the data of a study as relevant as the one we present today, allows us to measure the importance of universal access to health. At FIFARMA we support all regional initiatives which promote innovation, access to health and patients´ education to achieve a comprehensive and transparent health system “.

 

Author: Juan Carlos Trujillo de Hart   FIFARMA International Policy and Operations Director